OR WAIT 15 SECS
Leapcure has announced an enhanced portfolio of services focused on the successful recruitment, enrollment, and sustained engagement of patients in clinical studies. Specifically, Leapcure’s enhancements center on some of the biggest challenges facing Sponsors, Contract Research Organizations, and Investigator Sites, incorporating the patient voice to inform early development in the areas of public awareness, clinical feasibility, site selection, and recruitment.
With the addition of 200 new Patient Advocacy Partnerships this past month, Leapcure’s global public awareness reach now exceeds 3,500 health organizations, representing millions of patient voices. This level of access to patient networks is unique in the clinical trials industry, increasing engagement between patients and researchers in combination with Leapcure in:
Leapcure protocol-level feasibility services have been enhanced to assess if a clinical trial’s goals are ultimately achievable and that trial requirements that are designed with patients in mind to:
In regard to site selection, many clinical teams limit their consideration to sites meeting protocol requirements and sponsor regulatory goals, with only cursory recruitment planning. Leapcure incorporates recruitment viability, delivering the best experience for patients and forwarding sites that will be effective recruitment partners.
“Patient advocacy, patient insight and patient feedback are nothing new to the research space, ” Zach Gobst, CEO. “It’s all about advancements in how this information is captured and applied. We’re now able to help researchers evolve their view to capture this at a research strategy level, years before enrollment is set.”
Leapcure’s team has grown to 12, with plans to triple as the company continues to evolve its model and platform. Leapcure also announces new advisory board members engaged in growth strategy and implementation including Dawn Giles, President of Giles in Healthcare and former Parexel executive; Hope Horton, Director of Clinical Operations at Mavis; and Rodney Winley, Senior Director of Patient-Focused Clinical Trials at CSL Behring.